TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05459441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous progenitor expansion -T
Description: After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous progenitor expansion -T
Description: After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
Study: NCT05163236

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal immunochemical test (FIT) not performed
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal immunochemical test (FIT) not performed
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
Study: NCT05459441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
Study: NCT04581785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hLB-001
Description: hLB-001 via IV infusion
Study: NCT06506136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will receive fluoxetine tablets, 20 mg each, taken orally twice a day (total daily dose of 40 mg) for 12 weeks. Tablets should be taken with water at the same times daily.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.
Study: NCT06292520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portage Guide Protocol
Description: Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABLLS-R protocol
Description: ABLLS-R protocol will be given to this group
Study: NCT05090007

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: OTHER
Intervention: gut microbiota
Description: gut microbiota

Intervention type: OTHER
Intervention: gut microbiota
Description: gut microbiota
Study: NCT06258941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MF-HIIT
Description: Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT-only
Description: Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MF-only
Description: Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sedentary activity
Description: Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
Study: NCT05715658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate capsule
Description: Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
Study: NCT06000670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction injection in the osteoarthritic knee
Description: stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
Study: NCT05939752

Intervention type: OTHER
Intervention: ophthalmological examination
Description: OCT-retinal angiography At inclusion, 3 months and 6 months

Intervention type: BIOLOGICAL
Intervention: blood test
Description: a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion
Study: NCT06122103

Intervention type: DEVICE
Intervention: Clareon Monofocal
Description: Clareon Monofocal Intraocular Lens (toric and non-toric)

Intervention type: DEVICE
Intervention: Light-Adjustable Lens
Description: Light-Adjustable Lens (Intraocular Lens)
Study: NCT04335968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg
Description: melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo of this drug with the same schedule, during the same period of time.
Study: NCT05812937

Intervention type: PROCEDURE
Intervention: Intraabdominal ultrasound
Description: To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
Study: NCT06282419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USE OF MOBILE ULTRASOUND
Description: First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound image taken from the internet
Description: First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
Study: NCT05854069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMS-T1D
Description: FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Digital resources for diabetes
Description: Quality digital resources about diabetes management provided upon enrollment and during the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital resources for diabetes
Description: Quality digital resources about diabetes management provided upon enrollment and during the study.
Study: NCT05566288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: compressed film-coated tablet containing 3 mg cytisinicline
Study: NCT05977218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoodSwitch
Description: Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
Study: NCT06292767

Intervention type: OTHER
Intervention: mechanical power calculation
Description: Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation

Intervention type: OTHER
Intervention: mechanical power calculation
Description: Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
Study: NCT04728646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
Description: Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)

Intervention type: DEVICE
Group type: OTHER
Intervention: Regular dissolvable intracanalicular plug
Description: Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
Study: NCT04896853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProTrans®
Description: Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
Study: NCT06308744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body-scan meditation
Description: Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing meditation
Description: Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving Kindness meditation
Description: Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking
Description: Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening of a story
Description: Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
Study: NCT05968248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MLR-DBS
Description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional rehabilitation group
Description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
Study: NCT05269459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) as Nantheia ATL5
Description: Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
Study: NCT04652804

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity HCV treatment adherence support
Description: A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium intensity HCV treatment adherence support
Description: The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity HCV treatment adherence support
Description: The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
Study: NCT04793282

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone Follow-up
Description: Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Follow-up
Description: Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
Study: NCT05496361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tianyi Revascularization Device
Description: Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR Revascularization Device
Description: Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
Study: NCT05845619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced virologic monitoring
Description: The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000)).
Study: NCT05947825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of sitagliptin+ gemcitabine + nab-paclitaxel
Description: Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment.
Study: NCT06406530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Healing
Description: After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
Study: NCT05367622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation health education
Description: 1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual diabetes health education
Description: 1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education